Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  vemurafenib
Find trials that include:  Any drugs shown
Results 1-25 of 28 for your search:
Start Over
An Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol
Phase: Phase IV
Type: Treatment
Age: 18 and over
Trial IDs: GO28399, NCI-2013-01160, 2012-003144-80, NCT01739764
BRIM8: A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO27826, NCI-2012-03085, 2011-004011-24, G027826, NCT01667419
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CMEK162B2301, NCI-2013-01414, NCT01909453
Leflunomide and Vemurafenib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-088, NCI-2014-00593, NCT01611675
Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: P1446A-05/72/12, NCI-2013-02011, NCT01841463
Decitabine and Vemurafenib in Treating Patients with Stage IV Melanoma Who Have a BRAF Mutation
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201304715, NCI-2014-00838, ML28604, NCT01876641
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ML27894, NCI-2015-01305, GEN-01, NCT01495988
A Study of Zelboraf (Vemurafenib) in Patients With BRAF V600 Mutation-Positive Cancers
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MO28072, NCI-2012-00699, NCT01524978
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer and High Dose Aldesleukin in Treating Patients With Metastatic Melanoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC #16992, NCI-2012-01379, NCT01659151
Biomarkers in Predicting Response in Patients with Locally Advanced Thyroid Cancer Receiving Vemurafenib before Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2012-0471, NCI-2012-02171, 00000363, NCT01709292
Vemurafenib in Treating Patients with Relapsed or Refractory Hairy Cell Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-200, NCI-2012-02170, NCT01711632
Vemurafenib and Aldesleukin in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-343, NCI-2013-00283, NCT01754376
Vemurafenib in Treating Patients With Stage III-IV Melanoma That is Metastatic or That Cannot Be Removed By Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ML28305, NCI-2013-00664, 2012-1048, NCT01813214
A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf, and Erivedge Treatment Targeted Against Certain Mutations in Cancer Patients
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: ML28897, NCI-2014-01811, NCT02091141
Cobimetinib and Vemurafenib in Treating Patients with Melanoma That Has Spread To the Brain
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCI 13-123, NCI-2015-00016, ML29155, NCT02230306
BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 to 17
Trial IDs: NO25390, NCI-2012-00500, 2011-000874-67, NCT01519323
Vemurafenib with Sorafenib Tosylate or Crizotinib in Treating Patients with Advanced Malignancies with BRAF Mutations
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2011-1183, NCI-2012-00217, NCT01531361
Vemurafenib with Everolimus or Temsirolimus in Treating Patients with Advanced Cancer
Phase: Phase I
Type: Treatment
Age: Not specified
Trial IDs: 2012-0153, NCI-2012-00789, NCT01596140
Vemurafenib, Carboplatin, and Paclitaxel in Treating Patients with Advanced Solid Tumors or Lymphoma
Phase: Phase I
Type: Treatment
Age: 12 and over
Trial IDs: 2012-0394, NCI-2012-01221, NCT01636622
Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MCC-17013, NCI-2012-01380, NCT01657591
Hydroxychloroquine and Vemurafenib in Treating Patients With Stage IV Melanoma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 06613, NCI-2013-01350, 818066, NCT01897116
Vemurafenib and Recombinant Interferon alfa-2b in Treating Patients With Stage III-IV Melanoma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-107, NCI-2013-01876, PRO13040314, NCT01943422
Start Over